Loading data for SCNX — first visit, this takes a few seconds.

Scienture Holdings, Inc. (SCNX)

NasdaqCM: SCNX · 即時價格 · USD

0.35

-0.01 (-2.78%)

收盤價： Sep 11, 2026, 8:00 PM

0.35

+0.60%

盤後: 7:24 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	0.03
市值	14.3M
營收 (ttm)	821K
淨利（ttm）	-38M
	3.98
	-2.03
	n/a
	n/a
P/B (ttm)	0.22
P/S (ttm)	17.39
財報日期	n/a

賣價	0.4
成交量	238,640
20 日平均成交量	2,682,200
開盤價	0.36
前收盤價	0.36
當日區間	0.34 - 0.37
52 週範圍	0.24 - 2.60
分析師	n/a
目標價	n/a
股利	n/a
除息日	Jul 19, 2024

關於 SCNX

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left vent...

[閱讀更多]

產業 Pharmaceutical Retailers

類股 Healthcare

IPO 日期 Feb 6, 2014

員工 4

證券交易所 NasdaqCM

股票代號 SCNX

網站 https://scienture.com

完整的公司簡介

財務表現

Scienture s 在 2025 年的營收為 431.61K，較前一年的 136.64K 增加 215.87%。淨利為 -41.51M，較前期減少 -557.9%。

財務報表

財報驚奇

Scienture s 已於 Aug 13, 2026 公布季度財報：

營收為 $343.64K 低於預期 $0, 年增 Infinity% 成長.
每股盈餘為 -0.07 超出預期 0.02, 年增 -Infinity% 下滑.

價格為何變動

新聞動態

1 月前 · InvestorsHub

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U. S.

1 月前 · Benzinga

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

Pharmaceutical firm Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday officially initiated the commercial rollout of Rezenopy, a 10-milligram naloxone hydrochloride nasal spray. The company has succ...

3 月前 · Benzinga

EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

Scienture Holdings Inc. (NASDAQ:SCNX) said Tuesday that its opioid overdose treatment Rezenopy (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a large national health plan, broaden...

6 月前 · Associated Press Finance

BC-Most Active Stocks

Elong Power Holding Ltd. 79,546,080 0.0559

9 月前 · TipRanks

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

Scienture (SCNX) announced a strategic collaboration to expand national access to Arbli, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli is expected to be...

第 1 頁，共 2 頁

Scienture Holdings, Inc. (SCNX)